JP6294710B2 - Glucose metabolism improver - Google Patents

Description

  The present invention relates to a sugar metabolism improving agent.

  The number of diabetic patients in Japan is estimated to be about 8.9 million, the number of diabetic reserves is estimated to be about 13.2 million, and the number is increasing year by year. Japanese people are prone to diabetes, that is, they are less likely to consume the food they eat and can easily store them, and the generous gene possession rate is said to be 2 to 5 times that of Westerners. Therefore, prevention or treatment of diabetes is an important problem.

  Currently, as therapeutic drugs for diabetes, sulfonylurea agents (SU agents) that promote insulin secretion, phenylalanine derivatives, α-glycosidase inhibitors that suppress sugar absorption, and biquanides that suppress sugar production in the liver ( BG) drugs, thiazolidine derivatives that improve insulin resistance, and the like are known, but these drugs are prescribed only when diabetes is diagnosed, and those who belong to the diabetes reserve arm become diabetic. The only way to prevent progress is to rely on diet and exercise therapy.

  In order to improve the hyperglycemic state due to diabetes, it is desired to fundamentally improve sugar metabolism including the constitution, not transiently. In order to maintain a constitution that actively performs sugar metabolism, improvement of sugar metabolism by food therapy is considered promising as well as the aforementioned drugs.

  An object of this invention is to provide the component which has a sugar metabolism improvement effect, and also provides the food-drinks and sugar metabolism improving agent containing such a component.

  The inventors of the present invention have found that the seeds of plants belonging to the genus Moringa (genus Wasabino) have an effect of improving sugar metabolism in the process of earnestly studying to solve the above problems. As a result of further investigation, regarding the seeds of plants belonging to the genus Moringa (genus Wasabino), the aqueous extract does not show a significant improvement in sugar metabolism, but the lower alcohol extract has a very good sugar. It was found that there is an effect of improving metabolism. The present invention is based on such knowledge.

The present invention provides the following [1] to [8].
[1] An extract obtained by extracting seeds of a plant belonging to the genus Moringa (genus Wasabino) with a lower alcohol.
[2] The extract according to [1], wherein the lower alcohol is ethanol.
[3] A food and drink containing an extract obtained by extracting seeds of plants belonging to the genus Moringa (genus Wasabino) with a lower alcohol.
[4] Selected from the group consisting of (A) seeds of plants belonging to the genus Moringa (genus Wasabino) and (B) extracts obtained by extracting the seeds of plants belonging to the genus Moringa (genus Wasabino) with lower alcohols A sugar metabolism improving agent comprising one or more active ingredients.
[5] The sugar metabolism-improving agent according to [4], which contains, as an active ingredient, an extract obtained by extracting a seed of a plant belonging to (B) Moringa (Wasabinus) with a lower alcohol.
[6] The food or drink or sugar metabolism improving agent according to any one of [3] to [5], wherein the lower alcohol is ethanol.
[7] The food / beverage product or the sugar metabolism improving agent according to any one of [3] to [6], further comprising (C) an acid-treated product of a carrot family ginseng.
[8] The food or drink or sugar metabolism improving agent according to [7], wherein the ginseng is ginseng.

  ADVANTAGE OF THE INVENTION According to this invention, the component which has a sugar metabolism improvement effect can be provided, and by extension, the food-drinks and sugar metabolism improving agent containing such a component can be provided.

FIG. 1 is a diagram showing changes in blood glucose levels before and after intake of each group in Example 1. FIG. 2 is a graph showing changes in blood glucose levels before and after ingestion of each group in Example 2. FIG.

[Extract]
The extract of the present invention is obtained from seeds of plants belonging to the genus Moringa (genus Wasabino).

  Moringa is a deciduous plant that grows from Namibia, Madagascar, East Africa, the Arabian Peninsula, and the tropics to subtropics of India. Examples of the plant belonging to the genus Moringa (genus Wasabino) include Moringa oleifera, Moringa concanensis, Moringa drohardi and the like. These leaves, flowers and roots are used as flavored vegetables and spices.

  The present inventors have found that the seeds of plants belonging to the genus Moringa (genus Wasabino) have an effect of improving sugar metabolism. Here, the “sugar metabolism improving action” in the present invention means an action of suppressing an increase in blood sugar level and an action of lowering the blood sugar level.

  From the viewpoint of obtaining an extract having an excellent effect of improving sugar metabolism, Moringa oreifera is preferred as a plant belonging to the genus Moringa (genus Wasabino). Moringa oleifera is a deciduous Kotakagi native to India, and its scientific name is Moringa oleifera LAM. (M. ptergogosperma). Moringa Oleifera also has many aliases such as Horseradish tree, Ben nut, Malungai (Tagalog), Sanjanaa (Hindu).

  The seeds of plants belonging to the genus Moringa (genus Wasabino) may be used as they are, or after drying. In addition, the seed may be used with the outer skin attached, or may be used after the outer skin is removed. Seeds may also be used after being ground into a powder. When the seeds are pulverized into powder, the seeds with the outer skin attached or the seeds from which the outer skin has been removed can be pulverized with a pulverizer (for example, a wonder blender) to form powder. From the viewpoint of obtaining an extract excellent in an action for improving sugar metabolism, it is preferable to use a powdery body obtained by pulverizing a seed with an outer skin or a seed from which the outer skin has been removed.

  Commercial seeds may be used for the seeds of plants belonging to the genus Moringa (genus Wasabino). Commercial products can be purchased, for example, from AITEL Corporation.

  In obtaining an extract having an effect of improving sugar metabolism from seeds of plants belonging to the genus Moringa (genus Wasabino), it is important to extract the seeds by an organic solvent extraction method and / or a supercritical extraction method. In this regard, no significant sugar metabolism improving effect is observed in the aqueous seed extract.

  In addition, it is well known that different types of plants have different active ingredients. It is also well known that even in the same kind of plant, the active ingredients contained in each part such as seeds, stems, roots, etc. are different and the activity is different [for example, 1) Ministry of Health, Labor and Welfare, general use Pharmaceutical sales system “Guideline for Creating Examination Questions (August 2007)” Page 184 [online] [Search on March 4, 2013], Internet <URL: http://www.mhlw.go.jp /bunya/iyakuhin/ippanyou/shiken.html> 2) Supervised by Masayuki Yoshikawa, “Development of medicinal foods-Application of medicinal and useful plants to functional food materials-”, CM Publishing, February 2007, 68th See page]. Considering such circumstances, it is possible to obtain an extract having an action of improving sugar metabolism by extracting seeds of plants belonging to the genus Moringa (genus Wasabino) by an organic solvent extraction method and / or a supercritical extraction method. The knowledge in the present invention is something that could not be foreseen even if the plants belonging to the genus Moringa (genus Wasabino) have been used as leaves, flowers and roots as flavored vegetables and spices. In addition, the leaves, flowers, and roots of plants belonging to the genus Moringa have a specific smell and bitterness.

(Organic solvent extraction method)
In a preferred embodiment, the extract of the present invention is obtained by extracting seeds of a plant belonging to the genus Moringa (genus Horseskin) with an organic solvent.

  Examples of the organic solvent used for extraction include lower alcohols (monohydric or polyhydric alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, butanol, ethylene glycol, propylene glycol, butylene glycol, and glycerin), saturated Examples include hydrocarbons (pentane, hexane, heptane, etc.). An organic solvent may be used individually by 1 type, and 2 or more types may be mixed and used for it.

  Among these, from the viewpoint of obtaining an extract excellent in an action for improving sugar metabolism, the organic solvent is preferably a lower alcohol, more preferably a monohydric alcohol having 1 to 4 carbon atoms, and even more preferably ethanol.

  The organic solvent used for extraction preferably contains no water, but may contain a small amount of water. From the viewpoint of obtaining an extract excellent in an action for improving sugar metabolism, the content of water in the organic solvent used for extraction is preferably 5% by mass or less, more preferably 3% by mass or less, and further preferably 1% by mass or less. It is.

  The extraction may be carried out so that the mass ratio of the extraction solvent to the seed (extraction solvent / seed) is preferably in the range of 5 to 100, more preferably in the range of 5 to 50.

  The extraction temperature can be in the range from the melting point to the boiling point of the extraction solvent. Although depending on the type of the extraction solvent, the extraction temperature is preferably −20 ° C. to 78 ° C., more preferably 4 ° C. to 36 ° C., and further preferably 15 ° C. to 30 ° C.

  The extraction time is not particularly limited, but is usually in the range of 30 minutes to 2 days, and preferably in the range of 1 hour to 1 day.

  Extraction may be carried out under the above conditions, under stirring or in a stationary state. The extraction may also be performed while the extraction solvent is refluxed. The number of extractions is not particularly limited, and may be repeated a plurality of times.

  After extraction, the seed residue is removed by filtration, centrifugation, etc., and the extraction solvent is removed by decompression or the like to obtain the extract of the present invention as a solid.

(Supercritical extraction method)
In a preferred embodiment, the extract of the present invention is obtained by supercritical extraction of seeds of a plant belonging to the genus Moringa (genus Horseskin).

  As the solvent used for the supercritical extraction, a solvent having a critical temperature of 600 K or less is preferable. For example, carbon dioxide, saturated hydrocarbon (preferably saturated hydrocarbon having 1 to 4 carbon atoms), lower alcohol (preferably carbon number) 1-4 monohydric alcohols). Such a solvent may be used individually by 1 type, and 2 or more types may be mixed and used for it. When mixing and using 2 or more types of solvent, at least 1 type of solvent should just be in a supercritical state.

  Carbon dioxide is preferred as the solvent used for supercritical extraction because of its relatively low critical temperature and excellent handleability.

  The conditions for supercritical extraction vary depending on the solvent used, but when carbon dioxide is used, it is preferable that the temperature be 40 ° C. to 80 ° C., the pressure is 15 MPa to 45 MPa, and the extraction time is 1 hour to 6 hours.

  In supercritical extraction using carbon dioxide, the extract can be separated from carbon dioxide by reducing the pressure after extraction. When using other solvents such as lower alcohol in addition to carbon dioxide or in place of carbon dioxide, carbon dioxide is separated by lowering the pressure after extraction, and then, if necessary, by reducing the pressure. The other solvent may be removed.

  Since the extract of the present invention is excellent in an effect of improving sugar metabolism and excellent in flavor, it is easy to ingest an effective amount continuously. Therefore, food / beverage products and pharmaceuticals (sugar metabolism improving agents) containing the extract of the present invention are extremely useful in improving sugar metabolism. In addition, the glucose metabolism improving effect of the extract of the present invention can be evaluated using, for example, a hyperglycemia model mouse described later.

[Food and Drink]
The extract of the present invention can be used to provide a food or drink having an effect of improving sugar metabolism.

  Although the extract of the present invention is as described above, it is preferable to use an extract obtained by extracting seeds of a plant belonging to the genus Moringa (genus Wasabino) with a lower alcohol from the viewpoint of an action of improving sugar metabolism. . Therefore, in a preferred embodiment, the food or drink of the present invention contains an extract obtained by extracting seeds of a plant belonging to the genus Moringa (genus Wasabino) with a lower alcohol.

  In addition to the extract of the present invention, the food / beverage product of the present invention includes a ginseng ginseng, a ginseng extract and an acid-treated product, a saponin contained in the ginseng ginseng and its metabolite, panaxadiol, panaxatriol , Protopanaxadiol, and one or more components selected from protopanaxatriol (hereinafter also referred to as “auxiliary components”) may be contained.

  In addition to the extract of the present invention, by using the above auxiliary component, a food or drink that has a further excellent effect of improving sugar metabolism can be provided.

  In the above auxiliary component, examples of the ginseng ginseng include ginseng (also referred to as ginseng and ginseng), ginseng ginseng, etc., and ginseng ginseng is preferred.

  As the extract of the ginseng ginseng, an extract of a water extract or an acid-treated product is preferable, and an extract of an acid-treated product is more preferable. The acid-treated product extract is preferably obtained by, for example, solvent-extracting the acid-treated product obtained by the method described in International Publication No. 2010/029915. The solvent used for extraction of the acid-treated product is preferably an organic solvent. The kind of organic solvent, extraction conditions, and the like are the same as those described above for the extract of the present invention.

  The acid-treated product of Scarceae ginseng can be obtained by allowing a strong acid aqueous solution to act on Scarceae ginseng (details will be described later). The acid-treated product of Scarlet ginseng brings about an improved sugar metabolism action in combination with the extract of the present invention, which is superior to Sorghum ginseng itself. When the sea ginseng is treated with acid, the sugar is released from the saponins contained in the ginseng ginseng, and sapogenins (aglycone bodies) such as panaxatriol, panaxadiol, protopanaxatriol, and protopanaxadiol are produced. These sapogenins exhibit a glucose metabolism improving action superior to that of saponins as active ingredients, and are more absorbable in the body than saponins. In addition, the acid-treated product obtained by the method described later has high safety and is excellent in taste and handleability, so that it can be used as it is or after being appropriately treated, and in combination with the extract of the present invention. It can be suitably used as an active ingredient.

Examples of the saponins contained in the sea ginseng include ginsenoside-Rb ₁ , ginsenoside-Rd, ginsenoside-Rc, and ginsenoside-Rg ₁ .

  There are no particular restrictions on the method for obtaining sapogenin such as panaxadiol, panaxatriol, protopanaxadiol, and protopanaxatriol, and it can be selected appropriately according to the purpose. For example, ginseng ginseng May be a sapogenin-containing composition obtained by the method described in JP2011-12005A, or a sapogenin isolated from the sapogenin-containing composition.

  Among these, from the viewpoint of synergistically enhancing the effect of improving sugar metabolism in combination with the extract of the present invention, it is preferable to use an acid-treated product of Acarinaceae as an auxiliary component.

  Hereinafter, the manufacturing method of the acid-treated product of Scarinaceae will be described. In the following description, the sapogenin-containing composition can be suitably produced by replacing “Armyceae ginseng” with “saponin-containing plant”. The saponin-containing plant is not particularly limited as long as it contains saponin. In addition to plants belonging to the family Urugiaceae such as ginseng ginseng, for example, serie family, scallop family, asteraceae family, cucurbitaceae family, legume family, jade family Plants belonging to the family, Akebiaceae, Oleaceae, Lilyaceae, and Yamaceae.

〔Production method〕
An acid-treated product of Araliaceae ginseng is, for example, described in International Publication No. 2010/029915 and JP2011-12005A, after hydrolyzing Argentine ginseng in the presence of a strong acid aqueous solution and a lower alcohol. And may be obtained by filtration.

  Scarlet ginseng may be used as it is collected from nature, for example, by using it after performing pretreatment appropriately combining washing, drying, cutting, crushing, pulverization, etc. It is possible to more efficiently perform the hydrolysis treatment. Among these, it is preferable to use pulverized powdery ginseng as the ginseng ginseng. Note that commercially available ginseng may be used. Specific examples of commercially available products include rice ginseng powder, rice ginseng water extract extract powder (both manufactured by Matsuura Pharmaceutical Co., Ltd.), and the like.

  Hereinafter, a particularly preferable production method is exemplified from the viewpoint of efficiently obtaining the acid-treated product powder.

  In a preferred embodiment, the acid-treated product of Araceae ginseng is obtained by hydrolyzing Araceae ginseng in the presence of a strong acid aqueous solution having a predetermined concentration and a lower alcohol (hydrolysis treatment step), and the resulting hydrolysis treatment. It can be manufactured by neutralizing the subsequent liquid (neutralization step), filtering (filtration step), and drying the filtered residue (drying step).

<Hydrolysis process>
In the hydrolysis treatment step, a strong acid aqueous solution having a predetermined concentration is allowed to act on the ginseng ginseng to hydrolyze the saponins in the ginseng ginseng to produce sapogenins.

  The strong acid aqueous solution is not particularly limited as long as it is an aqueous solution containing a strong acid, and can be appropriately selected according to the purpose. Among them, an aqueous solution containing an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid is preferable. An aqueous solution containing hydrochloric acid is particularly suitable. The acid concentration in the strong acid aqueous solution is 0.01 mol / L to 4 mol / L, and preferably 0.5 mol / L to 3 mol / L. When the acid concentration is less than 0.01 mol / L, there is a problem that hydrolysis is insufficient and sapogenin is not efficiently generated. When the acid concentration exceeds 4 mol / L, hydrolysis proceeds excessively or cost is increased. The problem of disadvantages arises. On the other hand, when the acid concentration is within the preferable range, it is advantageous in terms of efficient sapogenin production by sufficient hydrolysis.

  It is preferable that the strong acid aqueous solution is used in an amount of 2 to 20 times the volume of the ginseng. When the amount of the strong acid aqueous solution used is less than 2 times the capacity of the ginseng ginseng, the ginseng ginseng is not sufficiently immersed and the hydrolysis treatment becomes insufficient. , It may be disadvantageous in terms of cost.

-Use of lower alcohol-
The hydrolysis treatment is more preferably performed in the presence of a lower alcohol. By using a lower alcohol, it is possible to improve the affinity between the ginseng ginseng and the strong acid aqueous solution, and to proceed the hydrolysis efficiently. In addition, the use of a lower alcohol is also advantageous in that the acid-treated product obtained can be improved in taste and handleability.
The lower alcohol is not particularly limited and may be appropriately selected depending on the intended purpose. Among them, methanol, ethanol and propanol are preferable, and ethanol is particularly preferable from the viewpoint of safety.

  There is no restriction | limiting in particular in the usage-amount of the lower alcohol in a hydrolysis process, Although it can select suitably according to the objective, It is preferable that it is 1-80 volume% with respect to a hydrolysis liquid total amount, 10-50 It is more preferable that it is volume%, and it is still more preferable that it is 20-40 volume%. When the amount of the lower alcohol used is less than 1% by volume relative to the total amount of the hydrolyzed liquid, sapogenin may not be efficiently generated. When it exceeds 80% by volume, sapogenin may not be efficiently generated. It may be disadvantageous in terms of cost. On the other hand, when the amount of the lower alcohol used is within the further preferable range, it is advantageous in terms of efficient production of sapogenin. The “total amount of hydrolyzed liquid” refers to the total amount of the reaction liquid including the strong acid aqueous solution and the lower alcohol.

  The total amount of the hydrolyzed liquid is not particularly limited and may be appropriately selected depending on the intended purpose. However, it is preferably 2 to 20 times the capacity of the carrot ginseng. If the total amount of the hydrolyzed liquid is less than twice the capacity of the carrot ginseng, the carrot carrot may not be sufficiently immersed and the hydrolysis treatment may be insufficient. May be disadvantageous.

  The treatment temperature in the hydrolysis treatment step is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 60 to 100 ° C and more preferably 70 to 90 ° C. If the treatment temperature is less than 60 ° C, hydrolysis may be insufficient and sapogenin may not be produced efficiently. If the treatment temperature exceeds 100 ° C, special production equipment is required, which is disadvantageous in terms of cost. Etc. On the other hand, when the treatment temperature is within the more preferable range, it is advantageous in terms of efficient production of sapogenin.

  The treatment time in the hydrolysis treatment step is not particularly limited and can be appropriately selected depending on the purpose, but is preferably 30 minutes to 24 hours, and more preferably 2 to 8 hours. If the treatment time is less than 30 minutes, hydrolysis may be insufficient and sapogenin may not be produced efficiently, and if it exceeds 24 hours, the reaction may proceed excessively or cost may be disadvantageous. is there. On the other hand, when the treatment time is within the more preferable range, it is advantageous in terms of efficient production of sapogenin.

<Neutralization process>
In the neutralization step, the hydrolyzed solution is neutralized.
Neutralization is not particularly limited and can be performed by a known method. For example, the neutralization can be performed by appropriately adding an aqueous solution of a strong base such as sodium hydroxide or potassium hydroxide to the solution after hydrolysis. it can. In addition, it is preferable to implement a neutralization process so that pH after neutralization may be 5-8.

<Filtering process>
In the filtration step, the liquid obtained in the neutralization step is filtered and separated into a filtrate and a residue.
Filtration is not particularly limited and can be performed by a known method. After filtration, washing with water may be repeated until there is no more salt.

-Hydrolysis-
When the hydrolysis treatment is performed in the presence of a lower alcohol, from the viewpoint of obtaining an acid-treated product having a high sapogenin content, before filtration, water is added to the solution obtained in the neutralization step to lower alcohol in the solution. It is preferable to reduce the concentration. In this case, the larger the amount of water added, the better. However, the lower alcohol concentration in the liquid obtained in the neutralization step may be reduced, specifically, it may be added to 50% by volume or less. Preferably, it is more preferably added so as to be 30% by volume or less, and still more preferably added so that it is 10% by volume or less.
If the lower alcohol concentration in the liquid obtained in the neutralization step is subjected to filtration while exceeding 50% by volume, the produced sapogenin is dissolved in the lower alcohol and discharged as a filtrate, and the sapogenin in the residue This is disadvantageous in that the content decreases. On the other hand, when the lower alcohol concentration in the liquid obtained in the neutralization step is within the further preferable range, it is advantageous in that the sapogenin content in the residue can be further increased.

-Vacuum concentration treatment-
From the viewpoint of obtaining an acid-treated product having a high sapogenin content, it is preferable to concentrate the liquid obtained in the neutralization step under reduced pressure before filtration. The lower alcohol concentration in the liquid can be lowered by distilling off the lower alcohol by concentration under reduced pressure. In this case, the concentration temperature is preferably 70 ° C. or lower, and more preferably 40 ° C. to 50 ° C. The concentration under reduced pressure is preferably carried out so that the lower alcohol concentration is preferably 50% by volume or less, more preferably 30% by volume or less, and still more preferably 10% by volume or less. When the liquid obtained in the neutralization step is subjected to filtration while the lower alcohol concentration in the liquid exceeds 50% by volume, the produced sapogenin is dissolved in the lower alcohol and discharged as a filtrate, and the residue This is disadvantageous in that the content of sapogenin in the medium is reduced. On the other hand, if the liquid obtained in the neutralization step is subjected to filtration after the lower alcohol concentration in the liquid falls within the further preferable range, it is advantageous in that the sapogenin content in the residue can be further increased. It is.
Moreover, although the said vacuum concentration process and the said hydration process may be performed before filtration as a single process, respectively, you may perform as a series of processes. When performing as a series of steps, the hydration treatment is performed after the vacuum concentration treatment.

<Drying process>
In the drying step, the residue obtained in the filtration step is dried to obtain an acid-treated product.
Drying is not particularly limited, and can be performed by a known method. For example, usual methods such as freeze drying, ventilation drying, heat drying, and reduced pressure drying can be used.

  In the above, the suitable method for manufacturing the acid-treated product of Scarinaceae was explained. In the above method, a powder of an acid-treated product of ginseng can be suitably produced, and the obtained acid-treated product has a high sapogenin content. As described above, in the above-described method, “saponin ginseng” is replaced with “saponin-containing plant”, whereby a sapogenin-containing composition can be suitably produced from saponin-containing plants other than sorghum ginseng. The sapogenin-containing composition thus obtained can also provide an excellent sugar metabolism improving action in combination with the extract of the present invention, and is suitable as an auxiliary component of the extract of the present invention.

  In a preferred embodiment, the food / beverage product of the present invention contains an extract obtained by extracting seeds of a plant belonging to the genus Moringa (genus Horseskin) with a lower alcohol and the auxiliary component.

  The optimum ratio of the mass ratio of the extract of the present invention to the auxiliary component (the extract of the present invention: auxiliary component) in the food and drink of the present invention varies depending on the type of the auxiliary component, but preferably 1: 0. It is 01-100, More preferably, it is 1: 0.1-30. In addition, when using said some component as an auxiliary | assistant component, the mass ratio calculated based on the total mass of this some component should just be in the said range.

  The food and drink of the present invention may further contain other components as long as the effects of the present invention are not impaired. Examples of other components include oil components, excipients, disintegrants, binders, lubricants, coating agents, colorants, color formers, flavoring agents, flavoring agents, antioxidants, antiseptics, and tastes. Selecting one or more types according to the dosage form of the food or drink as the final product from among optional components such as an agent, a sour agent, a sweetener, a fortifier, a swelling agent, a thickener, and a surfactant. it can.

  Examples of the oil component include fatty acid esters, hydrocarbons, higher fatty acids, higher alcohols, and the like.

  Examples of excipients include, for example, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, crystalline cellulose, ethylcellulose, cellulose such as low-substituted hydroxypropylcellulose and derivatives thereof, synthetic polymers such as polyvinylpyrrolidone and partially saponified polyvinyl alcohol, gelatin Polysaccharides such as gum arabic powder, pullulan, agar, alginic acid, sodium alginate, chitansan gum, starch such as corn starch, potato starch, pregelatinized starch, hydroxypropyl starch and derivatives thereof, lactose, fructose, glucose, sucrose, trehalose, Sugars such as palatinose, mannitol, sorbitol, erythritol, xylitol, reduced palatinose, powdered reduced maltose starch syrup, maltitol and the like Sugar alcohols, light anhydrous silicic acid, particulate silicon oxide, titanium oxide, and inorganic excipients such as aluminum hydroxide gel.

  Examples of the disintegrant include crospovidone, carmellose calcium, croscarmellose sodium, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl starch sodium, croscarmellose sodium, hydroxypropyl starch, and partially pregelatinized starch. It is done.

  Examples of the binder include hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, dextrin, starch, pregelatinized starch and the like.

  Examples of the lubricant include calcium stearate, magnesium stearate, sucrose fatty acid ester, light anhydrous silicic acid, sodium stearyl fumarate, polyethylene glycol, talc, stearic acid and the like.

  Examples of the dosage form of the food and drink according to the present invention include liquid (liquid), syrup (syrup), tablet (tablet, tablet), capsule (capsule), powder (granule, fine granule), and soft capsule. (Soft capsule), solid, semi-liquid, cream, and paste. For example, beverages (soft drinks, carbonated drinks, nutrition drinks, powdered drinks, fruit drinks, milk drinks, jelly drinks, etc.), confectionery (cookies, cakes, gums, candy, tablets, gummies, buns, sheep cakes, puddings, jelly, Ice cream, sherbet, etc.), processed fishery products (kamaboko, chikuwa, hanpen, etc.), processed livestock products (hamburg, ham, sausage, winner, cheese, butter, yogurt, fresh cream, margarine, fermented milk, etc.), soup (powder) And soup, liquid soup, etc., staple foods (rice, noodles (dried noodles, raw noodles), bread, cereals, etc.), seasonings (mayonnaise, shortening, dressing, sauce, sauce, soy sauce, etc.).

  The food and drink of the present invention include health foods, functional foods, health foods, health supplements (supplements), nutritional supplements, foods for specified health use, medical foods, foods for the sick, foods for infants, foods for nursing care, It can also be used as food and drink such as food for the elderly.

  The intake of the food or drink of the present invention is not particularly limited as long as the effects of the present invention are not impaired, and may be appropriately determined according to various factors such as the age and condition of the subject who takes the food and drink of the present invention. . In order to obtain the desired effect of improving sugar metabolism, the intake amount of the extract of the present invention is preferably 0.1 mg / day or more, more preferably 10 mg / day or more, and further preferably 45 mg / day or more. It is preferable to take the food and drink of the present invention. The upper limit of the intake amount of the food or drink of the present invention is not particularly limited, but even if a large amount is consumed, it does not contribute further to the improvement of the effect of improving glucose metabolism. Therefore, the intake amount of the extract of the present invention is preferably 10 g / It is preferable to ingest the food or drink of the present invention so that it is not more than a day, more preferably not more than 800 mg / day, and still more preferably not more than 180 mg / day. In a preferred embodiment, the intake of the food or drink of the present invention is preferably 0.1 mg / day to 10 g / day, more preferably 10 mg / day to 800 mg / day, as the intake of the extract of the present invention. More preferably, it can be determined to be 45 mg / day to 180 mg / day.

In recent years, the pathological conditions of diabetes have been classified into four categories: 1) normal range, 2) normal high level, 3) borderline range, and 4) diabetic range based on fasting blood glucose levels. The relationship between each disease state classification and fasting blood glucose level is shown below.
1) Normal region: less than 100 mg / dL 2) Normal high value: 100 mg / dL or more and less than 110 mg / dL 3) Boundary region: 110 mg / dL or more and less than 126 mg / dL 4) Diabetes region: 126 mg / dL or more

  Although the person who takes the food and drink of the present invention is not particularly limited, those who have a fasting blood glucose level in any of the above 2) normal high value, 3) boundary region, and 4) diabetes region are suitable. Those whose blood glucose level is in any of the above 2) normal high value and 3) boundary region are more preferable.

  As long as the effects of the present invention are exhibited, the food and drink of the present invention are used for animals other than humans (for example, mice, rats, hamsters, birds, dogs, cats, sheep, goats, cows, pigs, monkeys, etc.). It is also possible to apply.

[Sugar metabolism improving agent]
The sugar metabolism improving agent of the present invention contains seeds of plants belonging to the genus Moringa (genus Wasabino) and / or the extract of the present invention as active ingredients.

  As described above, the sugar metabolism improving action of the sugar metabolism improving agent of the present invention includes an action of suppressing an increase in blood sugar level and an action of lowering the blood sugar level. Therefore, in one embodiment, the sugar metabolism improving agent of the present invention functions as a blood sugar level increase inhibitor. In another embodiment, the glucose metabolism-improving agent of the present invention functions as a blood glucose level-lowering agent.

  The extract that can be contained in the sugar metabolism-improving agent of the present invention is as described above. From the viewpoint of the sugar metabolism-improving action, it is obtained by extracting seeds of plants belonging to the genus Moringa (genus Wasabino) with lower alcohol. It is preferred to use an extract.

  Therefore, in a preferred embodiment, the sugar metabolism-improving agent of the present invention comprises (A) seeds of plants belonging to the genus Moringa (genus Wasabino) and (B) seeds of plants belonging to the genus Moringa (genus Wasabino) to lower alcohol. 1 or more selected from the group consisting of extracts obtained by extraction in (1).

  (A) The seeds of plants belonging to the genus Moringa (genus Wasabino) used as a component may be used as they are, or may be used after drying. In addition, the seed may be used with the outer skin attached, or may be used after the outer skin is removed. Seeds may also be used after being ground into a powder. When the seeds are pulverized into powder, the seeds with the outer skin attached or the seeds from which the outer skin has been removed can be pulverized with a pulverizer (for example, a wonder blender) to form powder. From the viewpoint of usability and formulation, it is preferable to use, as the component (A), a powdery body obtained by pulverizing the seed with the hull attached or the seed from which the hull has been removed.

  From the viewpoint of the action of improving sugar metabolism, the sugar metabolism-improving agent of the present invention may contain, as an active ingredient, an extract obtained by extracting (B) seeds of plants belonging to the genus Moringa (genus Wasabino) with a lower alcohol. preferable.

  There is no restriction | limiting in particular in content of the said (A) component in the sugar metabolism improving agent of this invention, and (B) component, You may select suitably according to the objective.

  The sugar metabolism improving agent of the present invention may contain other components in addition to the components (A) and (B). There is no restriction | limiting in particular as long as the effect of this invention is not impaired as another component, For example, the support | carrier accept | permitted pharmacologically is mentioned.

  The pharmacologically acceptable carrier may be appropriately selected according to the dosage form of the sugar metabolism improving agent of the present invention, and examples thereof include ethanol, water, starch and the like.

  The sugar metabolism improving agent of the present invention may also contain the above-mentioned auxiliary components and optional components described for the food and drink.

  The administration form of the sugar metabolism improving agent of the present invention is not particularly limited. For example, oral administration (eg, oral administration, sublingual administration, etc.), parenteral administration (intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, nasal administration, pulmonary administration, etc.) and the like can be mentioned. Among these, administration forms with less invasiveness are preferable, and the sugar metabolism improving agent of the present invention is more preferably an oral administration agent.

  Examples of the dosage form when the sugar metabolism improving agent of the present invention is an oral administration agent include, for example, liquid (liquid), syrup (syrup), tablet (tablet, tablet), capsule (capsule), and powder. (Granule, fine granule), soft capsule (soft capsule), liquid (liquid), solid, semi-liquid, cream, and paste.

  The dosage of the sugar metabolism-improving agent of the present invention is not particularly limited as long as the effects of the present invention are not impaired, and may be appropriately determined according to various factors such as the age and condition of a living body to be administered. In order to obtain the desired effect of improving sugar metabolism, the dose of the component (A) is preferably 0.3 mg / day or more, more preferably 30 mg / day or more, further preferably 150 mg / day or more, Alternatively, the sugar metabolism-improving agent of the present invention is administered so that the dose of component (B) is preferably 0.1 mg / day or more, more preferably 10 mg / day or more, and even more preferably 45 mg / day or more. Is preferred. The upper limit of the dose of the sugar metabolism-improving agent of the present invention is not particularly limited, but even if it is administered in a large amount, it does not contribute any further to the improvement of the effect of improving glucose metabolism, so the dose of component (A) is preferably 50 g. / Day or less, more preferably 4 g / day or less, more preferably 900 mg / day or less, or the dose of component (B) is preferably 10 g / day or less, more preferably 800 mg / day or less, It is preferable to administer the sugar metabolism improving agent of the present invention so that the dose is preferably 180 mg / day or less. In a preferred embodiment, the dosage of the sugar metabolism-improving agent of the present invention is preferably 0.3 mg / day to 50 g / day, more preferably 30 mg / day to 4 g / day, as the dosage of component (A). More preferably 150 mg / day to 900 mg / day, or the dose of component (B) is preferably 0.1 mg / day to 10 g / day, more preferably 10 mg / day to 800 mg / day, Preferably, it can be determined to be 45 mg / day to 180 mg / day.

  The subject of administration of the sugar metabolism-improving agent of the present invention is not particularly limited, but those who have a fasting blood glucose level in any of the above 2) normal high value, 3) border zone, and 4) diabetic zone are suitable. A person whose blood glucose level is in any of 2) normal high value and 3) boundary region is more preferable.

  As long as the effect of the present invention is exhibited, the sugar metabolism-improving agent of the present invention is an animal other than a human (for example, mouse, rat, hamster, bird, dog, cat, sheep, goat, cow, pig, monkey, etc.) It is also possible to apply to.

  The method for evaluating the effect of improving sugar metabolism is not particularly limited and may be appropriately selected depending on the purpose. As a method for evaluating the effect of improving glucose metabolism, for example, a method of evaluating with a hyperglycemia model mouse can be mentioned.

  The method for evaluating with a hyperglycemic model mouse is not particularly limited. The method of measuring the blood glucose level after raising is mentioned.

  Examples of the hyperglycemia model mouse include KKAy mouse (Nippon Claire Co., Ltd.), ZDF rat (Nippon Charles River Co., Ltd.) and the like. For example, there is no restriction | limiting in particular as normal food, You may use commercial items, such as CE-2 (Nippon Claire Co., Ltd.). Moreover, there is no restriction | limiting in particular as a high fat meal, For example, you may use commercial items, such as Quick-Fat (Nippon Claire Co., Ltd.).

  The breeding period of the hyperglycemia model mouse is not particularly limited and may be appropriately selected depending on the intended purpose. For example, it may be 4 days to 65 days. The amount of the sugar metabolism-improving agent of the present invention given to the hyperglycemic model mouse is 0.03 mg / day to 400 mg / day as the amount of component (A), or 0.01 mg / day as the amount of component (B). A range of 100 mg / day is preferred. This is equivalent to 20 mg / day to 200 g / day as the amount of component (B) when converted to the dose of a human weighing 60 kg.

  Hereinafter, the present invention will be described in detail with reference to examples. The following examples are for explaining the present invention preferably, and the present invention is not limited to the following examples.

Each sample blended in a high fat diet in the following examples is shown below.
<Morringa seed pulverized product>
The pulverized moringa seeds were obtained by pulverizing Moringa oleifera seeds (Indian PKMI; Aitel Co., Ltd.) using a pulverizer (Wonder Blender; Osaka Chemical Co., Ltd.).
<Moringa seed hot water extract>
Distilled water (10 mL) was added to 1 g of pulverized moringa seeds, stirred at 90 ° C. for 2 hours, and then filtered using filter paper. The obtained extract was freeze-dried to obtain a hot water extract of Moringa seeds.
<Moringa seed ethanol extract>
10 mL of 99.5% ethanol (special grade reagent; manufactured by Wako Pure Chemical Industries, Ltd.) was added to 1 g of pulverized moringa seeds, stirred at room temperature (25 ° C.) for 2 hours, and then filtered using filter paper. The obtained extract was dried under reduced pressure using a rotary evaporator (manufactured by Tokyo Rika Kikai Co., Ltd.) to obtain an ethanol extract of Moringa seeds.
<Acid-treated product of Tanachi ginseng>
1 kg of ginseng powder (manufactured by Matsuura Pharmaceutical Co., Ltd.) into a mixed solution of 1.585 L of 5.9% by mass hydrochloric acid (2 mol / L hydrochloric acid), 2.37 L of 99.9% by mass ethanol aqueous solution, and 6.045 L of water. The suspension was suspended and heated at 80 ° C. for 6 hours with slow stirring to perform acid hydrolysis treatment. Subsequently, after cooling the obtained mixed liquid on ice, 5 mol / L sodium hydroxide aqueous solution was added, and it neutralized so that it might become pH 7.0. The liquid after neutralization was subjected to suction filtration. The obtained residue was heated and dried under reduced pressure to obtain 180 g of powder (acid-treated product of ginseng).

Example 1
A hyperglycemic model mouse (KKAy mouse (Japan) was obtained by free intake using a diet containing 1% of each sample shown in Table 1 below for a commercially available high fat diet (trade name: Quick-Fat, manufactured by Claire Japan). Claire Co., Ltd.), 4 week old pupae, 4-5 animals / group) were bred for 7 days (hereinafter also referred to as “sample composition group”). As a control, a sample-free feed (that is, only the above-mentioned commercially available high fat diet) was used (hereinafter also referred to as “sample-free group”).
About each group, the blood glucose level before breeding (before administration) and the blood glucose level after breeding (after administration) were measured by One Touch Ultra (manufactured by Johnson & Johnson Co., Ltd.). The measurement was performed at 10:00 am, and the average value was adopted as the blood glucose level of each group. Variations in data are shown by standard error, and statistical analysis was performed by Student's T test. The results are shown in Table 1 and FIG.

From Table 1 and FIG. 1, the blood sugar level significantly increased in 7 days in the sample-unblended group (control) compared to before breeding (before administration). In the sample-blended group fed with the food blended with moringa seed hot water extract, the blood glucose level increased to the same extent as the sample-unblended group.
In the sample blended group fed with the moringa seed pulverized blend, the increase in blood glucose level was suppressed with a significant tendency at a risk rate of 5% or more and less than 10% compared to the sample unmixed group.
In the sample blended group fed with the food blended with Moringa seed ethanol extract, the increase in blood glucose level was significantly suppressed at a risk rate of less than 5% compared to the sample unblended group and Moringa seed hot water extract blended group. . Furthermore, an increase in blood glucose level was significantly suppressed at a risk rate of less than 5% for the moringa seed crushed material combination group.
From the above results, it was recognized that Moringa seeds have an effect of suppressing the increase in blood glucose level, and that the ethanol extract has an effect of suppressing the increase in blood glucose level higher than that of the moringa seed crushed material.

Example 2
A hyperglycemia model mouse (freely ingested) using a diet containing 1% of each sample (converted to solid matter) shown in Table 2 below with respect to a commercially available normal diet (trade name: CE-2, manufactured by CLEA Japan, Inc.) KKAy mice (CLEA Japan, 4 weeks old, 6-7 mice / group) were bred for 35 days. In addition, about sample combination group using combination of Moringa seed ethanol extract and Tannin ginseng acid processed product, Moringa seed ethanol extract 1% (Solid matter conversion), Tannin ginseng acid treated product 1% (Solid matter conversion) ) Was used in combination with 2% of the total sample. As a control, a sample-free feed (that is, only the above-mentioned commercially available normal diet) was used.
For each group, the blood glucose level before administration (day 0 of administration) and the blood glucose level after administration (days 1 to 35 of administration) were measured by One Touch Ultra (manufactured by Johnson & Johnson Co., Ltd.). The measurement was performed at 10:00 am and the average value was adopted as the blood glucose level of each group. Variations in data are shown by standard error, and statistical analysis was performed by Student's T test. The results are shown in Table 2 and FIG.

From Table 2 and FIG. 2, in the sample-free group (control), the blood glucose level increased as the number of administration days increased, compared to the blood glucose level before administration (day 0 of administration) (also referred to as “initial value”). did.
Moringa seed ethanol extract blended group and Tannin ginseng acid treated blended group (hereinafter collectively referred to as “single sample blended group”) are compared to the sample unblended group on the 28th and 35th day of administration. The blood glucose level was significantly decreased with a risk rate of 5% or less.
A sample combination group (hereinafter, also referred to as “combination sample combination group”) fed with a combination of a Moringa seed ethanol extract and a rice ginseng treated product was administered (14th and 21st days after administration). In all the measurements on the 28th and 35th days, the blood glucose level was significantly decreased with a 5% risk rate with respect to the sample-free group. The combination sample combination group also showed a significantly lower blood glucose level at a risk rate of 5% or less than the single sample combination group on the 28th and 35th days of administration. Further, the single sample combination group showed a significant blood glucose level with a significant tendency at a risk rate of 5% or less with respect to the initial value on the 35th day after administration, whereas the combination sample combination group showed the initial value on the 35th day after administration. In contrast, the blood glucose level was low.

  As described above, although the single sample combination group showed a lower blood glucose level than the sample non-mixing group, the blood glucose level increased as the number of administration days increased, and the blood glucose level was higher than the initial value. In contrast, the combination sample combination group showed not only an increase in blood glucose level even when the number of administration days increased, but also showed a low blood glucose level relative to the initial value although not significant.

  When the rate of increase in blood glucose level from day 0 to day 35 of administration in the sample-free group is 100%, the rate of increase in blood glucose level from day 0 to day 35 of administration in the single sample combination group is About 40%, the rate of increase in blood glucose level from day 0 to day 35 of administration in the combination sample combination group was about -9%. Based on the results of the rate of increase in blood glucose level of the single sample combination group, the additive result of the rate of increase in blood glucose level that can be considered when Moringa seed ethanol extract and the seven ginseng acid-treated products are used in combination is 16 % (= 40% × 40%), which is largely different from the rate of increase in blood glucose level (about −9%) confirmed for the combination sample combination group. That is, it was confirmed that when the Moringa seed ethanol extract and the seven ginseng acid-treated products were administered in combination, the blood glucose level increase inhibitory effect was synergistically exhibited.

Claims (4)

  A sugar metabolism-improving agent comprising, as an active ingredient, an extract obtained by extracting seeds of a plant belonging to the genus Moringa (genus Wasabino) with ethanol.   A food and beverage composition for improving sugar metabolism, comprising an extract obtained by extracting seeds of a plant belonging to the genus Moringa (genus Wasabino) with ethanol.   Furthermore, the sugar-metabolism improving agent or food-drinks composition for glucose metabolism improvement of Claim 1 or 2 containing the acid-processed material of the ginseng ginseng.   The sugar metabolism improving agent or food / beverage composition for improving sugar metabolism according to claim 3, wherein the ginseng is ginseng.